Sigma Planning Corp Lowers Position in Biohaven Ltd. (NYSE:BHVN)

Sigma Planning Corp lessened its position in Biohaven Ltd. (NYSE:BHVN) by 50.1% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 6,418 shares of the company’s stock after selling 6,447 shares during the quarter. Sigma Planning Corp’s holdings in Biohaven were worth $275,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. FSC Wealth Advisors LLC raised its stake in Biohaven by 50.0% during the third quarter. FSC Wealth Advisors LLC now owns 15,000 shares of the company’s stock valued at $390,000 after buying an additional 5,000 shares during the last quarter. Raymond James & Associates raised its stake in Biohaven by 104.3% during the third quarter. Raymond James & Associates now owns 27,545 shares of the company’s stock valued at $716,000 after buying an additional 14,065 shares during the last quarter. Weybosset Research & Management LLC raised its stake in Biohaven by 19.7% during the third quarter. Weybosset Research & Management LLC now owns 12,140 shares of the company’s stock valued at $316,000 after buying an additional 2,000 shares during the last quarter. Strs Ohio raised its stake in Biohaven by 99.2% during the third quarter. Strs Ohio now owns 24,100 shares of the company’s stock valued at $626,000 after buying an additional 12,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Biohaven by 13.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 38,071 shares of the company’s stock valued at $990,000 after buying an additional 4,540 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Insider Buying and Selling

In other news, Director Gregory Bailey acquired 25,503 shares of the business’s stock in a transaction that occurred on Wednesday, April 24th. The stock was bought at an average price of $39.18 per share, with a total value of $999,207.54. Following the completion of the acquisition, the director now directly owns 1,600,071 shares of the company’s stock, valued at approximately $62,690,781.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Vlad Coric purchased 121,951 shares of the business’s stock in a transaction on Monday, April 22nd. The stock was acquired at an average price of $41.00 per share, with a total value of $4,999,991.00. Following the completion of the acquisition, the chief executive officer now owns 1,788,417 shares of the company’s stock, valued at approximately $73,325,097. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Gregory Bailey purchased 25,503 shares of the business’s stock in a transaction on Wednesday, April 24th. The shares were bought at an average cost of $39.18 per share, with a total value of $999,207.54. Following the acquisition, the director now directly owns 1,600,071 shares of the company’s stock, valued at approximately $62,690,781.78. The disclosure for this purchase can be found here. Insiders bought 196,234 shares of company stock valued at $7,999,179 over the last 90 days. Company insiders own 16.00% of the company’s stock.

Biohaven Trading Up 1.1 %

Biohaven stock opened at $38.97 on Friday. The firm has a market cap of $3.44 billion, a price-to-earnings ratio of -6.89 and a beta of 1.18. The stock has a fifty day simple moving average of $50.90 and a two-hundred day simple moving average of $41.86. Biohaven Ltd. has a 12 month low of $12.35 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.40). On average, equities research analysts forecast that Biohaven Ltd. will post -5.81 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

BHVN has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, March 4th. TD Cowen lifted their price objective on Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. lifted their price objective on Biohaven from $32.00 to $56.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. UBS Group lifted their target price on Biohaven from $59.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday, April 23rd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price on shares of Biohaven in a report on Tuesday, April 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Biohaven currently has an average rating of “Buy” and an average target price of $52.13.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.